Colorectal polyposis (no specific type) – risk management

ID: 1423 v.4 **Endorsed**

Summary

This descriptive diagnosis represents a heterogeneous group of conditions, with a broad spectrum of polyp and colorectal cancer risk.

The management of individuals with a personal or family history of polyposis of unknown cause should be tailored to the history of colorectal polyps and cancer. This risk management guideline has been developed for individuals who have **NOT** been diagnosed with a colorectal cancer. The care of **affected** individuals should be individualised based on their clinical situation, and the monitoring they need as part of their treatment and post-treatment follow up.

Target group

- Individuals with a personal and/or family history of colorectal polyposis sufficient for genetic testing to be done AND
- Uninformative genetic testing in polyp-affected relative AND
- Do not meet one of the exclusion criteria below.

Exclusion criteria

- Individuals with a pathogenic variant in a gene that predisposes to colorectal polyposis (e.g. APC, MUTYH, STK11).
- UNTESTED individuals in a family with an identified pathogenic variant in a gene that predisposes to colorectal polyposis (e.g. APC, MUTYH, STK11).
- Individuals with a clinical diagnosis of a familial colorectal polyposis syndrome (e.g. serrated polyposis syndrome, juvenile polyposis syndrome).

Lifetime risk of cancer

Not defined (see comments above).

Cancer risk management guidelines

Patients should be managed on an individual basis using both personal clinical features and family history.

Individuals with adenomatous polyposis and their first degree unaffected relatives could consider management guidelines based on 2018 NCCN guidelines – refer to table .

References

Bibliography

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – Colonic Adenomatous Polyposis of Unknown Etiology – Version 1.2018

History

Version 4

Date	Summary of changes
05/09/2019	Protocol reviewed at the May 16 2019 reference committee meeting. Discussions continued via email. Protocol published with the following changes made: • Summary: wording updated • Target group: 'polyp-affected relative' added to second bullet point • Cancer risk management guidelines - second paragraph added and link to table adapted from the 2018 NCCN guidelines (ACI ID 3665) • Reference updated • Definition of "pathogenic variant" added as a pop-up. Protocol version number increased to V.4. To be reviewed in 2 years.

Version 3

Date	Summary of changes
19/12/2016	Discussed at October 2015 reference committee meeting, discussions continued via email and protocol published on eviQ. Next review in 2 years.
31/05/2017	Transferred to new eviQ website. Version number changed to V.2.
22/08/2019	Protocol title changed from 'Risk management for familial colorectal polyposis (no specific type)' to 'Colorectal polyposis (no specific type) – risk management' in accordance with Cancer Genetics Reference Committees' consensus. Version number increased to V.3.

First approved: 19 December 2016
Last reviewed: 5 September 2019
Review due: 5 September 2021

The currency of this information is guaranteed only up until the date of printing, for any updates please check:
https://www.eviq.org.au/p/1423
25 Sep 2019